Details of the Drug Reposition

General Information of This Drug (ID: DMR4HIW)

Drug Name
Insulin-glargine   DMR4HIW
Synonyms Glargine; Lantus; SoloStar; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin
Therapeutic Class
Hypoglycemic Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-insulin dependent diabetes DISK1O5Z 5A11 Approved [1]
Diabetic complication DIS4S2FC 5A2Y Approved [2]
------------------------------------------------------------------------------------
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Malaria DISQ9Y50 1F40-1F45 Phase 3 [3]
Type-1 diabetes DIS7HLUB 5A10 Phase 3 [4]
------------------------------------------------------------------------------------

References

1 Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7572).
3 ClinicalTrials.gov (NCT02059161) A Study of the Safety and Efficacy of MK-1293 Compared to Lantus in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)